Member of the European Academy of Sciences and Arts
Richard Greil mainly focuses on Internal medicine, Oncology, Surgery, Breast cancer and Immunology. Richard Greil combines topics linked to Gastroenterology with his work on Internal medicine. His work carried out in the field of Oncology brings together such families of science as Trastuzumab, Phases of clinical research, Anastrozole, Capecitabine and Retrospective cohort study.
The Surgery study which covers Adverse effect that intersects with Clinical trial. Richard Greil has researched Breast cancer in several fields, including Prospective cohort study, Gynecology and Chemotherapy regimen. His Immunology research incorporates elements of Cytotoxic T cell and Cancer research.
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Surgery and Chemotherapy. His Gastroenterology research extends to the thematically linked field of Internal medicine. His work is dedicated to discovering how Oncology, Docetaxel are connected with Epirubicin and other disciplines.
His Breast cancer research includes themes of Zoledronic acid, Adjuvant, Hazard ratio and Endocrine system. His Surgery research is multidisciplinary, incorporating perspectives in Dexamethasone and Rituximab. Richard Greil combines subjects such as Thalidomide and Bortezomib with his study of Dexamethasone.
His primary areas of study are Internal medicine, Oncology, Breast cancer, Cancer research and In patient. Richard Greil regularly links together related areas like Gastroenterology in his Internal medicine studies. Richard Greil interconnects Pembrolizumab, Pancreatic cancer, Metastatic breast cancer, First line and Gemcitabine in the investigation of issues within Oncology.
His Breast cancer research is multidisciplinary, incorporating elements of Colorectal cancer and Randomized controlled trial. His Cancer research research is multidisciplinary, relying on both T cell, Leukemia, Chronic lymphocytic leukemia and Gene. The concepts of his T cell study are interwoven with issues in Phase i study and Immune therapy.
Richard Greil focuses on Internal medicine, Oncology, Chemotherapy, Cancer research and In patient. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. His Oncology study integrates concerns from other disciplines, such as Pembrolizumab, Survival rate and Phases of clinical research.
His work deals with themes such as Stage, FOLFOX and Pancreatic ductal adenocarcinoma, which intersect with Chemotherapy. His study in Cancer research is interdisciplinary in nature, drawing from both Exome sequencing, B-cell receptor, T cell, CD3 and Chronic lymphocytic leukemia. His studies in Breast cancer integrate themes in fields like Liquid biopsy, Carcinoembryonic antigen, Oncogene and Toxicity.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study
Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières.
The Lancet (2019)
Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
Hans Theodor Eich;Volker Diehl;Helen Görgen;Thomas Pabst.
Journal of Clinical Oncology (2010)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno;Richard Greil;Fatih Demirkan;Alessandra Tedeschi.
Lancet Oncology (2019)
Randomized Phase II Study of the Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer
José Baselga;Patricia Gómez;Richard Greil;Sofia Braga.
Journal of Clinical Oncology (2013)
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
M. Gnant;M. Filipits;R. Greil;H. Stoeger.
Annals of Oncology (2014)
AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer
Luca Gianni;Gilles H. Romieu;Michail Lichinitser;Sergio V. Serrano.
Journal of Clinical Oncology (2013)
Drug-induced Apoptosis Is Associated with Enhanced Fas (Apo-1/CD95) Ligand Expression but Occurs Independently of Fas (Apo-1/CD95) Signaling in Human T-Acute Lymphatic Leukemia Cells
Andreas Villunger;Alexander Egle;Marion Kos;Bernd L. Hartmann.
Cancer Research (1997)
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
M. Gnant;B. Mlineritsch;H. Stoeger;G. Luschin-Ebengreuth.
Annals of Oncology (2015)
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group.
Peter Borchmann;Helen Goergen;Carsten Kobe;Andreas Lohri.
The Lancet (2017)
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Georg Pfeiler;Robert Königsberg;Christian Fesl;Brigitte Mlineritsch.
Journal of Clinical Oncology (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: